Surgery News and Research

RSS

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

6 May 2010

Preoperative process at High Pointe Surgery Center now online

In response to patient request, High Pointe Surgery Center in Minnesota has taken its preoperative process online. Since deploying One Medical Passport by Medical Web Technologies, the facility reports increased patient satisfaction, better utilization of staff and tangible cost savings.

6 May 2010

Cohera Medical reports top-line results from Tissuglu clinical trial

Cohera Medical, Inc.® today announced that top-line clinical study results demonstrate the safety and preliminary effectiveness of the company's lead surgical adhesive product, TissuGlu®.

6 May 2010

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.

6 May 2010

Obesity epidemic may be flattening out - still much to be done

The prevalence of childhood obesity might be stabilising in developed countries, but there is still much to be done to combat this major threat to health, according to a Seminar published on Online First and in an upcoming issue of The Lancet.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Officials investigate if use of surgical robot led to injuries

The Wall Street Journal: Injuries at a small New Hampshire hospital that uses a surgical robot have some questioning the use of such machines in the care of people. The machine, which is named after Leonardo da Vinci, has been linked to surgeries where patients have been hurt, including two with lacerated bladders and one woman who required four subsequent surgeries after errors using the machine.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

DGIMED ORTHO receives 510(k) clearance for DISTALOCK Titanium Femoral Intramedullary Nail system

DGIMED ORTHO, Inc. announced today that the company has received notification of clearance of its 510(k) submission for the DISTALOCKTM Titanium Femoral Intramedullary Nail system. In November 2009, the Company also received its initial clearance on the DISTALOCKTM Drill system with a stainless steel femoral IM nail.

6 May 2010

TearScience completes $44.5 million Series C funding

TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.

5 May 2010

BioTime first-quarter total revenue up 159% to $767,127

BioTime, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments.

5 May 2010

Study reveals changes in brain activity in response to withdrawal of life support

At a time when "donation after cardiac death" (DCD) has become an important approach to increasing the number of transplant organ donors, a provocative new study shows changes in brain activity occurring in response to withdrawal of life support, reports the May issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

5 May 2010

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

It is estimated that between 75 and 85 percent of all Americans will suffer from low back pain and/or neck pain at some point in their lives. An estimated 12 million Americans suffer from degenerative disc disease, with over one million patients undergoing surgery each year. The cost of treating back pain is currently estimated at more than $100 billion annually in the U.S. Many patients with back pain have comorbidities that impact spine surgery.

5 May 2010

Investment report on Misonix from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Misonix Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010

Pre-treatment quality-of-life scores predict malignancy in patients with pancreatic disease

Quality-of-life measures used routinely to assess treatment outcomes for patients with pancreatic disease may be used to predict both malignancy and survival for those patients, according to a study by Henry Ford Hospital.

5 May 2010

AAA symposium features digital technologies in anatomical reconstruction

Techniques for using digital technology in separating conjoined twins, developing facial prostheses and acquiring data from anthropologic specimens will be among the topics presented at a symposium sponsored by the American Association of Anatomists (AAA; www.Anatomy.org) on April 28. The symposium is part of the Experimental Biology 2010 conference being held April 24-28, 2010 at the Anaheim Convention Center.

5 May 2010

Pay-for-performance may create unintended financial incentives for doctors to discriminate against obese patients

Pay-for-performance reimbursement models may create unintended financial incentives for doctors to discriminate against obese patients, measuring a patient's waist circumference may be more effective in predicting surgical outcomes than the more traditional body mass index measure, and childhood obesity doubles the risk of developing colon cancer, according to data being presented at Digestive Disease Week- 2010.

5 May 2010

New treatments for intestinal failure, other intestinal absorption disorders

New treatments for intestinal failure and other intestinal absorption disorders are a step closer to the patients who need them after a discovery in Kelly Tappenden's University of Illinois laboratory.

5 May 2010

Researchers analyze role of gender in treatment and outcome of patients with MMD

Moyamoya disease is an uncommon, progressive cerebrovascular disease in which the main arteries feeding the brain (the intracranial internal carotid arteries/ICA and Circle of Willis) are narrowed or occluded on both sides, reducing blood flow to the brain. This causes transient episodes of reversible stroke with loss of neurologic function in the form of weakness of a limb, sensory disturbances, epileptic seizures or headaches.

5 May 2010

Surgery News and Research

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

Preoperative process at High Pointe Surgery Center now online

Cohera Medical reports top-line results from Tissuglu clinical trial

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Obesity epidemic may be flattening out - still much to be done

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Officials investigate if use of surgical robot led to injuries

Update on CEL-SCI's Phase III clinical trial of Multikine

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

DGIMED ORTHO receives 510(k) clearance for DISTALOCK Titanium Femoral Intramedullary Nail system

TearScience completes $44.5 million Series C funding

BioTime first-quarter total revenue up 159% to $767,127

Study reveals changes in brain activity in response to withdrawal of life support

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

Investment report on Misonix from MicroStockProfit.com

Pre-treatment quality-of-life scores predict malignancy in patients with pancreatic disease

AAA symposium features digital technologies in anatomical reconstruction

Pay-for-performance may create unintended financial incentives for doctors to discriminate against obese patients

New treatments for intestinal failure, other intestinal absorption disorders

Researchers analyze role of gender in treatment and outcome of patients with MMD

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News